Literature DB >> 29863795

Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.

Maria Cho1, Yumi Nonomura1, Yo Kaku1, Shuichiro Nakabo2, Yuichiro Endo1, Atsushi Otsuka1, Kenji Kabashima1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29863795     DOI: 10.1111/1346-8138.14492

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  6 in total

Review 1.  Cancer and Scleroderma.

Authors:  Emma Weeding; Livia Casciola-Rosen; Ami A Shah
Journal:  Rheum Dis Clin North Am       Date:  2020-06-10       Impact factor: 2.670

Review 2.  The relationships between cancer and autoimmune rheumatic diseases.

Authors:  Laura C Cappelli; Ami A Shah
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-02-03       Impact factor: 4.098

3.  Scleroderma-like syndrome associated with pembrolizumab.

Authors:  Silvia Suárez-Díaz; Rubén Coto-Hernández; Carmen Yllera-Gutiérrez; Carlos Álvarez-Fernández; Luis Trapiella-Martínez; Luis Caminal-Montero
Journal:  J Scleroderma Relat Disord       Date:  2020-02-18

Review 4.  Skin Manifestation Induced by Immune Checkpoint Inhibitors.

Authors:  Toshiyuki Yamamoto
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-05-10

5.  Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.

Authors:  Ewan A Langan; Kaja Budner; Detlef Zillikens; Patrick Terheyden
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

Review 6.  Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors.

Authors:  Alexandre Thibault Jacques Maria; Léo Partouche; Radjiv Goulabchand; Sophie Rivière; Pauline Rozier; Céline Bourgier; Alain Le Quellec; Jacques Morel; Danièle Noël; Philippe Guilpain
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.